- Virtual
The evolving landscape for biosimilars
Where
Virtual
When
{{getUserDateTimeZone("1633021200").singleDate}}
{{getUserDateTimeZone("1633021200").time}} - {{getUserDateTimeZone("1633024800").time}} {{getClientTimeZoneName()}}
About
Biosimilars were anticipated to be a solution to the soaring cost of prescription medicines to treat a slew of diseases. Have they reached their potential?
Some see encouraging signs of increased adoption rates for these treatments, which are made from living cells and nearly identical to their biologic counterparts. Others fear they are meeting resistance.
STAT’s Ed Silverman will convene a discussion on what it will take to create a functioning biosimilar market in the U.S.
Speakers:
- Madelaine A. Feldman, M.D., FACR, president, Coalition of State Rheumatology Organizations; clinical assistant professor of medicine, Tulane University School of Medicine
- Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president, biosimilars, Cardinal Health
- Gillian Woollett, principal research scientist, Avalere Health
More events in "Biotech"
Here’s an antidote to the rising cost of innovation: meet the pioneers who are leading the way to a new era of medicine, all in one place.…
Come for two days of silo-breaking and solution-focused discussions on the most important topics in health care. Sign up to get notified whe…
